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Alzheimer disease (AD) is characterized by a low level of acetylcholine, beta-amyloid (Aβ) aggregation 
and oxidative stress. Donepezil is the core medicine used for the treatment of AD. Various structural 
modifications of donepezil have been carried out. Benzylpiperidine part of donepezil has been replaced 
with benzylpyridine, pyridyl methylpiperidine, benzylpiperazine, pyrimidyl piperazine. These derived 
molecules showed promising activities as anti-Alzheimer agents. Replacement of indanone part by other 
heterocyclic rings such as pyridine resulted in the formation of compounds which exhibited monoamine 
oxidase (MAO) as well as acetylcholinesterase (AChE) inhibition. Propargylamine containing derivatives 
displayed AChE as well as MAO inhibition properties. Attachment of donepezil with natural compounds 
like ferulic acid, flavonoids, and curcumin showed antioxidant activities in addition to inhibition of the 
AChE. Benzylpiperidine and benzylpiperazine have also been combined with condensed heterocyclic 
rings and these compounds displayed promising anti-Alzheimer properties. This review highlights 
the important structural modifications of donepezil and their influence on biological activities as anti-
Alzheimer agents. 
Keywords: Acetylcholinesterase (AChE). Butyrylcholinesterase (BuChE). Benzylpiperidine. Indanone. 
Hybrid compounds.
INTRODUCTION
The Alzheimer disease (AD) is a neurodegenerative 
disorder and is characterized by premature senile mental 
deterioration. It mainly affects the elder people aged 
above 65 years (Naj et al., 2011). At present, 36 million 
people are affected due to this disease all over the world 
and according to some estimates, this number will 
increase up to 115 million in 2050 (Bolea et al., 2011). 
Characteristic features of this disease are memory loss, 
cognitive impairment, behavioural changes and eventual 
death (Scarpini, Scheltens, Feldman, 2003). Low level of 
acetylcholine is one of the major causes in the development 
and progress of this disease (Talesa, 2001). Alteration in 
the dopaminergic, serotoninergic and monoaminergic 
neurotransmission also contribute to some symptoms of 
Alzheimer disease. Beta-amyloid (Aβ) aggregation and 
oxidative stress are the other causes of this disease (Gella, 
Durany, 2009; Selkoe, Podlisny, 2002). Accumulation of 
metal ions also results in fatal neurologic disorders and 
it is closely associated with abnormal Aβ plaques (Bush, 
2008). Donepezil, rivastigmine, and galanthamine are 
the drugs which increase acetylcholine concentration 
by inhibiting cholinesterases and are effective in the 
treatment of AD (Birks, Harvey, 2006; Leon, Garcia, 
Marco-Contelles, 2013). An N-methyl-D-aspartate 
receptor antagonist, memantine is also approved for the 
treatment of this disease (David et al., 2012). Donepezil is 
a selective inhibitor of AChE and this drug was approved 
for the treatment of AD in 1996 (Doody, Cummings, 
Farlow, 2012). Donepezil is a well tolerated and is most 
effective AChE inhibitor without causing hepatotoxicity. 
The benzylic portion of donepezil combines with the 
catalytic anionic site (CAS) and dimethoxy indanone 
part combines with the peripheral anionic site (PAS) of 
AChE enzyme (Cheung et al., 2012). The AD is very 
complex in nature and involves many factors. Therefore, 
a drug molecule which interacts with a single receptor or 
enzyme is not sufficient for the treatment of this disease. 
Hybrid molecular strategy, in which the pharmacophoric 
parts of two drugs are combined in a single molecule, 
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is widely being used for designing the new donepezil 
derivatives (Leon et al., 2013). Over the last couple 
of years, a number of donepezil derivatives have been 
prepared and evaluated as anti-Alzheimer agents. 
To find the new derivatives, N-benzyl piperidinium 
and 5,6-dimethoxyindanone parts of donepezil have 
been attached as well as replaced by various other 
pharmacophores. In this review, an attempt has been 
made to summarize these derivatives on the basis of 
chemical structures and their biological activities as 
anti-Alzheimer agents. 
DONEPEZIL DERIVED COMPOUNDS
Donepezil molecule comprises benzylpiperidine 
part which is connected to dimethoxy indanone through 
methylene group (Figure 1). It is used as a racemic 
mixture. Various structural modifications of this drug have 
been carried out and they are described in the following 
sections. 
Benzylpiperidine, benzylpyridine, pyridyl 
methylpiperidine fragments attached to indanone
Costanzo et al. (2016) carried out the synthesis 
of donepezil derivatives in which benzylpiperidine 
and indanone part were connected through the double 
bond. Compounds 2 (Figure 2) and 3 showed the most 
active inhibition of human erythrocytes AChE having 
IC50 values of 0.058 ± 0.033 μM and 0.043 ± 0.007 
μM respectively. These compounds were found to be 
selective for AChE as compared to butyrylcholinesterase 
(BuChE) with selectivity values of 81 and 132 for 
compounds 2 and 3 respectively (Costanzo et al., 2016). 
Azzouz et al. synthesized bioxidiazable prodrugs of 
donepezil in which N-benzylpyridinium quaternary 
amine fragment was attached to indanone, tetralone 
and acetophenone fragments. Prominent activity was 
displayed by N-benzylpyridinium quaternary amine 
having the indanone ring. Compound 4  showed 
prominent inhibition of human AChE enzyme having 
an IC50 value of 0.36 nM. Docking studies of compound 
4 showed that indanone part interacted with PAS while 
N-benzyl group interacted with CAS of AChE. Carbonyl 
group of indanone part formed hydrogen bonding with 
Phe295 of AChE (Azzouz et al., 2018). Lan et al. carried 
out the synthesis of new donepezil derivatives in which 
5,6-dimethoxy indanone part of donepezil was conjugated 
with N-benzylpyridinium moiety. Compound 5 presented 
activity as cholinesterase inhibitor having IC50 values 
of 1.9 nM and 0.8 nM for electric eel AChE and human 
AChE respectively. Aβ aggregation inhibitory activity 
(53.7%) and antioxidant activity (0.54 Trolox equivalent) 
were also demonstrated by this compound. Compound 
5 was also found to be neuroprotective at the dose of 
1.56-12.5 μM. Compound 5 showed interaction with the 
CAS as well as with the PAS of AChE and showed the 
mixed type of inhibition (Lan et al., 2017). Wang et al. 
modified the benzyl group of donepezil with various 
other heterocyclic rings such as pyridine, quinoline 
and hydroxyquinoline and small groups were also 
introduced at these heterocyclic rings. Compound 6 
exhibited prominent inhibition of the AChE having IC50 
values of 85 nM and 73 nM for electric eel AChE and 
human AChE respectively. Compound 6 also inhibited 
the Aβ1-42 aggregation (46.3%) induced by copper 
(Cu+2) and showed neuroprotective effects. Molecular 
modeling studies showed a strong binding interaction 
of this compound with the CAS and PAS of AChE 
(Wang et al., 2016). Renou et al. (2016) synthesized 
four donepezil derivatives in which benzyl group of 
donepezil was replaced by 3-hydroxy pyridinaldoxime. 
Newly synthesized oxime derivatives showed the 
capacity to re-activate VX (an organophosphorous nerve 
reagent) and inhibited the human AChE better than 
the standard drug pralidoxime. Compound 7 showed 
the prominent activation of human BuChE (5 to 11 
fold higher) as compared to pralidoxime (Renou et al., 
2016). Zurek, Szymański and Mikiciuk-Olasik (2013) 
synthesized donepezil derivatives by incorporating 
hydrazine nicotinate to the indanone part. Derivatives 
in this series showed a higher affinity for AChE than 
BuChE. Compound 9  was the most active AChE 
inhibitor (IC50 = 1.087 ˟ 10 -5 μM) and also showed 
selectivity (selectivity index= 248.776) for this enzyme. 
An increased AChE inhition was observed by replacing 
piperidine with benzylpiperidine and the resulting 
compound 9 appeared to be more active than compound 
8. Docking studies of compound 9 showed a binding 
score of -181.939 with AChE using cache software 
(Żurek, Szymański, Mikiciuk-Olasik, 2013).
FIGURE 1 - Structural formula of donepezil.
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Benzylpiperidine attached to aromatic rings other 
than indanone
Özer et al. attached benzylpiperidine with the 
aromatic rings through an acylhydrazone group. These 
compounds were moderately active and nonselective as 
AChE and BuChE inhibitors. Compound 10 (Figure 3) 
was the most active in this series having IC50 values of 
53.1 ± 4.56 μM and 67.3 ± 5.24 μM for AChE and BuChE 
enzymes respectively. Docking studies also showed 
the π-π interaction with PAS and CAS site of human 
AChE. These compounds showed excellent inhibition 
(69-80%) of the Aβ aggregation and have the potential 
for further modifications (Özer et al., 2013). N-benzyl-
piperidine-aryl-acylhydrazone derivatives were prepared 
by Viegas et al. (2018) and among these, compound 12 
presented excellent inhibition of electrophorus electricus 
AChE with an IC50 value of 8.65 μM. Compounds 11 
and 12 also exhibited the inhibition of COX-1 (51% and 
64% for 11 and 12) and COX-2 (65% and 53% for 11 
and 12) enzymes. The interaction with COX enzymes 
was also confirmed by molecular docking studies. 
These compounds also showed neuroprotective ability 
(Viegas et al., 2018). N-benzylpiperidine part of donepezil 
was attached with the beta-secretase (BACE-1) inhibitor 
through isophthalamide group to produce the new hybrid 
molecules. New molecules showed dual inhibition of 
AChE and BACE-1 enzymes and compound 13 was 
most prominent having IC50 values of 1.83 ± 0.12 μM, 
0.567 ± 0.159 μM for AChE and BACE-1 respectively. 
This compound also reduced the production of Aβ 
(IC50 = 98.7 nM) and showed protection against hydrogen 
peroxide (H2O2) induced cytotoxicity (Zhu et al., 2009). 
In 2017 attached the optical isomers of glutamic acid 
(D and L glutamic acid) with N-benzylpiperidine part 
of donepezil. L-glutamine derivatives were found to be 
more active than D-glutamine. Compound 14 showed 
prominent activity having IC50 values of 4.99 ± 0.16 μM 
and 0.40 ± 0.02 μM for AChE and BuChE respectively. 
Compound 14 contains carboxy benzyl side chain 
(Monjas et al., 2017). 
Benzylpiperidine attached with heterocyclic rings 
Samadi et al. (2012) synthesized new pyridonepezil 
derivatives by linking the N-benzylpiperidine part 
FIGURE 2 - Benzylpiperidine, benzylpyridine and pyridyl methypiperidine derivatives.
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of donepezil and 2-aminopyridine heterocyclic ring. 
Compounds 15 (IC50 = 0.0094 ± 0.0004 μM) (Figure 4) 
and 16 (IC50 = 0.070 ± 0.005 μM) showed prominent AChE 
inhibitory activity as well as selectivity (S.I. = 703, 24 
for compound 15 and 16 respectively) for human AChE 
than human BuChE (Samadi et al., 2012). An year later, 
Samadi et al. (2013) synthesized 6-chloropyridonepezil 
derivatives and compound 17 displayed the most active 
inhibition of human AChE (IC50 = 0.013 ± 0.002 μM) 
and human BuChE (IC50 = 8.13 ± 0.0004 μM). These 
compounds showed the ability to cross the BBB. Docking 
studies revealed that compound 17 interacted with the 
CAS and PAS of the AChE (Samadi et al., 2013). Li et al. 
(2016) synthesized donepezil derivatives by linking the 
benzylpiperidine part of donepezil with benzamide and 
picolinamide moiety from an MAO inhibitor lazabemide. 
These compounds displayed AChE, BuChE, MAO-A and 
MAO-B inhibitory activities. Compound 18 presented 
the most potent inhibition of cholinesterases having IC50 
values of 0.220 μM, 1.23 μM and 0.454 μM for electric 
eel AChE, equine BuChE and human AChE respectively. 
This compound also showed inhibition of MAO-A and 
MAO-B having IC50 values of 3.14 μM and 13.4 μM. 
Compound 18 showed the capacity to cross the BBB 
and also exhibited metal chelating property. Docking 
studies of compound 18 with MAO-B demonstrated 
that 5-chloropicolinamide interacted with hydrophobic 
pocket while the N-benzylpiperidine bound via π-cation 
interaction with MAO-B (Li et al., 2016). 
Indanone derivatives having aromatic and 
heterocyclic rings
Yerdelen et al. (2015) attached the indanone part of 
donepezil with substituted aromatic rings through the amide 
group. Compound 19 (Figure 5) was the most prominent 
FIGURE 3 - Benzylpiperidine attached with aromatic rings.
FIGURE 4 - Benzylpiperidine attached with heterocyclic rings.
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inhibitor (IC50 = 0.08 ± 1.83 μM) of AChE and it was 
most selective (SI = 40.1) for this enzyme. Compound 19 
exhibited the most prominent inhibition of Aβ (55.3% at 
25 μM) aggregation. Compound 19 also showed bonding 
interactions with CAS and PAS in the AChE binding 
sites (Yerdelen et al., 2015). Meng et al. synthesized new 
donepezil derivatives in which the indanone part was 
connected to the pyridine ring through the double bond. 
Upon evaluation as AChE and BuChE inhibitor, compound 
20 showed the most prominent inhibition of AChE having 
an IC50 value of 0.0018 μM and selectivity (5248.6) for 
AChE as compared to BuChE. It was more potent than the 
standard drugs donepezil and tacrine. Compound 20 also 
showed prominent metal chelating ability (Meng et al., 
2012). Nan DD et al. synthesized 6-methoxy indanone 
derivatives and evaluated them as probes for β amyloid 
plaques. Iodine (125I) radiolabelled derivative (21) showed 
better binding to the β amyloid plaque, higher uptake in the 
brain and rapid clearance. Compound 21 also showed better 
penetration across BBB having a partition coefficient of 3.45 
(Nan et al., 2016). Rizzo et al. (2010) attached indanone part 
of donepezil to the phenyl-N-methylbenzylamino fragment 
from AP2238. Compound 22 showed prominent inhibition 
(46.8 ± 2.0%) of AChE induced Aβ aggregation. Derivatives 
23 and 24 showed prominent AChE inhibitory activities 
having IC50 values of 0.056 ± 0.003 μM and 0.052 ± 0.002 
μM respectively. These compounds contain pentamethylene 
chain connecting diethylamine and piperidine group with 
the tetralone part. Compounds 23 and 24 also showed 
the Aβ aggregation inhibition induced by AChE having 
the inhibitory values of 42.9 ± 0.8% and 48.3 ± 0.9%. 
Compounds 23 and 24 also inhibited the self-aggregation of 
Aβ. The long alkyl chain of these compounds having amino 
group showed a better interaction with PAS (Rizzo et al., 
2010). Mishra et al. carried out the synthesis of new 
5,6-dimethoxy indanone-piperazine derivatives in which 
FIGURE 5 - Indanone derivatives having aromatic and heterocyclic rings.
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structural parts of donepezil, curcumin and piperazine ring 
were combined to produce new molecules. Compounds 
25 and 26 showed excellent AChE inhibitory potential 
having IC50 values of 0.034 ± 0.002 μM and 0.025 ± 0.001 
μM and showed selectivity (SI = 28.5 and 97.3 for 25 and 
26 respectively) for AChE than BuChE. Compounds 25 
and 26 showed excellent inhibition of the Aβ aggregation 
(80.4 ± 1.08%, 81.6 ± 0.78% for 25 and 26 respectively) 
and antioxidant (3.89 ± 0.01, 2.34 ± 0.03 for 25 and 26 
respectively) activities. Molecular docking studies showed 
that these compounds have good interaction with AChE 
and Aβ peptide. Pyrimidine part of 26 binds through π-π 
interaction with PAS of AChE while the indanone part 
forms the hydrophobic interaction with CAS (Mishra et al., 
2017). Synthesis of new donepezil derivatives was carried 
out by Saglik et al. and their inhibitory effect on AChE 
was investigated. Compounds 27-30 displayed prominent 
inhibition of this enzyme (89.14-90.31% inhibition) and 
were found to be nontoxic (IC50 = 78-320 μM) on NH/3T3 
cell line. Side chains having another basic centre at the 
position # 4 of piperazine ring produced compounds with 
significant activity. Molecular docking studies also showed 
the interaction between these derivatives and targeted 
enzyme. Long chains of these compounds increased the 
van der Waals interactions with target enzyme (Sağlık, 
Ilgın, Özkay, 2016). Ismail et al. used indole molecule as 
the bioisosteric replacement of indanone part of donepezil. 
These compounds exhibited prominent AChE inhibitory 
activity and compound 31 was the most active (55% 
inhibition) derivative in this series. Molecular docking 
studies of this compound also showed good energy score 
(-23.4711 kcal/mol) in the active site of AChE. This was 
related to the additional 3-oxo and 2-fluorobenzyl groups 
in this compound (Ismail et al., 2012a). 
Phthalimide derivatives
Mohammadi-Farani et al. (2013) carried out 
the synthesis of donepezil derivatives in which the 
phthalimide ring was used in place of indanone part of 
donepezil. It was connected to benzylpiperazine through 
an alkyl chain. In this series, compound 32 (Figure 6) 
was the most prominent inhibitor of AChE having an 
IC50 value of 0.91 μM. This compound contains ortho 
chloro substituent attached to the phenyl ring. Therefore 
electron withdrawing groups increased the activity of 
phthalimide derivatives. The molecular modeling study of 
this compound showed that piperazine, phthalimide and 
benzyl group occupied the same position at the AChE as 
the piperidine, indanone and benzyl group of donepezil 
(Mohammadi-Farani et al., 2013). Ignasik et al. (2012) 
synthesized 2-(diethylaminoalkyl)-isoindoline-1,3-dione 
derivatives in which the phthalimide fragment was used as 
a substituent to indanone part of donepezil. Dialkylamine 
was used as a part which binds with the CAS. Compound 
35 was the most prominent derivative in this series having 
FIGURE 6 - Phthalimide derived compounds.
Donepezil: A review of the recent structural modifications and their impact on anti-Alzheimer activity
Braz. J. Pharm. Sci. 2020;56:e18325 Page 7 / 16
an IC50 value of 0.9 μM for AChE. It contains an alkyl 
chain of eight methylene units. Compounds 33 and 34 also 
showed the promising and selective inhibition of AChE 
having IC50 values of 1.2 μM and 1.1 μM. Docking studies 
of these compounds also showed interaction with AChE 
only. Compounds 33 and 34 also exhibited the inhibition 
(33.8% and 39.4% for 33 and 34) of Aβ aggregation 
(Ignasik et al., 2012). Sang et al. (2017) carried out the 
synthesis of new molecules comprising phthalimide and 
4-amino tetrahydrothienoquinoline. The reaction was 
done by direct alkylation of 37a-e with 36 and 38. These 
compounds have the potential for evaluation as AChE 
inhibitors (Song, Jo, 2009).
Donepezil and ferulic acid hybrid molecules
Ferulic acid is a phenolic compound which is found 
abundantly in plants. Donepezil and ferulic acid hybrids 
compounds were synthesized by Benchekroun et al. 
Resultant molecules showed prominent antioxidant 
activity and also showed selective inhibition of equine 
BuChE. Compounds 49 (Figure 7) and 50 were most 
active inhibitors of the BuChE having IC50 values 
of 10.39 ± 0.48 nM and 20.1 ± 1.9 nM respectively. 
Compounds 49 and 50 exhibited oxygen radical absorbing 
capacity of 8.71 ± 0.20 μmol and 8.48 ± 0.33 μmol 
respectively. These compounds contain ethylene and 
propylene linkers respectively and both of them contain 
melatonin as part of their structure (Benchekroun et al., 
2015). Dias et al. also synthesized donepezil-ferulic acid 
hybrid molecules by combining their pharmacophores. 
Compound 51 exhibited prominent activity against AChE 
having an IC50 value of 0.46 μM. Molecular docking studies 
showed the interaction of this compound with AChE with 
the docking score of -16.129 with free AChE and -16.956 
with acetylated AChE. Phenyl ring, the nitrogen atom of 
piperidine ring, a carbonyl group and 2-methoxyphenol 
ring of this compound interacted with AChE enzyme. 
Compound 51 also showed anti-inflammatory potential 
by inhibiting COX-1, COX-2 and lipooxygenase (5-LOX) 
enzymes. This compound also showed metal chelating 
capacity with certain metals along with neuroprotective 
effects (Dias et al., 2017). Sang et al. carried out the 
synthesis of ferulic acid-O-alkylamine derivatives by 
attaching the benzylpiperidine part of donepezil with 
ferulic acid and secondary amines by using methylene 
spacer. These compounds showed BuChE inhibitory and 
antioxidant activity. Compound 52 appeared as the most 
excellent inhibitor of BuChE (IC50 = 0.021 μM) and AChE 
(IC50 = 2.13 μM). Compound 52 also showed the inhibition 
of Aβ (50.8 ± 0.82%) aggregation. It also showed the 
ability to cross the BBB as well as less toxicity. Molecular 
modeling studies of compound 52 presented cation-π 
interaction, π-π interactions and hydrophobic interactions 
with BuChE but only hydrophobic interactions were 
observed with AChE which may be the reason for its 
selectivity for BuChE (Sang et al., 2017). Xu et al. (2016) 
combined the pharmacophores of donepezil and ferulic 
acid to produce new hybrid molecules. Compound 53 
displayed the prominent inhibition of electric eel AChE 
and equine BuChE having IC50 values of 0.398 μM and 
0.976 μM respectively. Significant antioxidant activity 
(1.78 Trolox equivalents) was also observed for this 
compound. Molecular docking studies showed that 
compound 53 binds with PAS by polar contacts of phenyl 
propanoid group and with CAS by the π-π interaction of 
the phenyl ring (Xu et al., 2016).
Donepezil and tacrine hybrid compounds
Tacrine was the first compound used for the 
treatment of AD but it was withdrawn from the market due 
to the toxic side effects. 7-Methoxytacrine is a less toxic 
derivative of tacrine (Soukup et al., 2013). Alonso et al. 
FIGURE 7 - Donepezil and ferulic acid hybrid molecules.
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reported the synthesis of donepezil and tacrine hybrid 
compounds in which indanone part of donepezil was 
replaced by phthalimide ring. These derivatives showed 
more selectivity for AChE as compared to BuChE. 
Compounds 54 and 55 (Figure 8) displayed excellent 
inhibition of the AChE enzyme having IC50 values of 
2.8 nM and 2.4 nM respectively. These compounds 
have the linker chain length of 9 and 12 methylene units 
between 9-aminoacridine and phthalimide scaffold. 
Molecular modeling of compounds 54 and 55 revealed 
that tetrahydroacridine/acridine rings of these compounds 
interacted with the catalytic site. Phthalimide ring attached 
with the peripheral site of AChE. Aromatic ring nitrogen 
formed hydrogen bonding while the chlorine atom 
interacted with hydrophobic pocket (Alonso et al., 2005). 
Synthesis of donepezil and tacrine hybrid molecules was 
carried out by Camps et al. in which the 5,6-dimethoxy-
2-(4-piperidylmethyl) 1-indanone piperidine part of 
donepezil was attached to the tacrine. These compounds 
showed prominent inhibition of AChE and BuChE 
enzymes. Compound 56 was most potent having an IC50 
value of 0.27 ± 0.03 nM for human AChE. Compound 57 
was the most prominent inhibitor (65.9 ± 2.5% inhibition) 
of Aβ aggregation. Tetrahydroacridine ring of compound 
56 attached with the catalytic site of AChE while ring 
nitrogen formed hydrogen bonding with the carbonyl 
oxygen of His447 of enzyme and chlorine atom occupies 
the hydrophobic pocket (Camps et al., 2008). Sepsova et al. 
(2015) evaluated 7-methoxytacrine and donepezil hybrid 
molecules for their interaction with AChE, with muscarinic 
and nicotinic acetylcholine receptors and these compounds 
presented activity in the micromolar range. They also 
showed the capacity to penetrate into CNS. Compound 
58 (IC50 = 1.38 ± 0.15 μmol/litre) was the most potent 
FIGURE 8 - Hybrid molecules comprising donepezil and tacrine fragments.
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AChE inhibitor and showed a mixed type of inhibition 
i.e. competitive and non-competitive (Sepsova et al., 
2015). Hybrid molecules comprising 7-methoxytacrine 
and donepezil were synthesized by Korabecny et al. 
(2014) in which benzylpiperazine acted as isostere of the 
benzylpiperidine fragment of donepezil. The synthesized 
compounds exhibited excellent cholinesterase inhibitory 
activity against human and animal cholinesterases. 
Compounds 59, 60, 61 were prominent having IC50 values 
of 1.12 ± 0.11 μM, 1.16 ± 0.22 μM and 1.94 ± 0.26 μM 
against human AChE while 62 was the most active inhibitor 
of human BuChE with an IC50 value of 0.42 ± 0.01 μM. 
Molecular modeling investigations showed the interaction 
of these derivatives with the CAS and PAS of the AChE. 
4-Bromophenyl group of compound 59 forms a new π-π 
interaction with enzyme and showed a binding energy of 
-13.8 kcal/mol (Korabecny et al.,2014). Misik et al. (2015) 
evaluated 7-methoxytacrine and N-benzylpiperazine 
hybrid molecules as AChE inhibitors and compound 63 
showed prominent inhibition (11.3%) of this enzyme as 
compared to donepezil (41%). Compound 63 contains 
benzylpiperazine group in place of benzylpiperidine 
fragment of donepezil (Misik et al., 2015). 
Donepezil hybrids with natural compounds
Compounds isolated from natural sources serve as 
lead compounds for new drug development (Koehn, Carter, 
2005). Natural compounds have been combined with 
benzylpiperidine part of donepezil and these molecules 
demonstrated anti-Alzheimer activities. Xie et al. 
combined N-benzylpiperidine part of donepezil with 
coumarin to produce new molecules having cholinesterase 
and MAO-B inhibitory activities. Compound 64 (Figure 9) 
appeared as the most active inhibitor of human AChE 
and human BuChE with IC50 values of 1.37 ± 0.05 μM 
and 1.98 ± 0.08 μM respectively. Compound 64 also 
showed inhibition of the MAO-B with an IC50 value of 
2.62 ± 0.81 μM. Molecular modeling studies showed that 
phenyl group of coumarin ring binds with PAS through π-π 
interaction and carbonyl oxygen forms hydrogen bonding 
with PAS. N-benzylpiperidine forms π-π interaction 
with CAS of AChE. Compound 64 showed the capacity 
to cross the BBB and was found non-toxic for HepG2 
cell line (Xie et al., 2016). Yan et al. synthesized new 
molecules by combining pharmacophores of donepezil 
and curcumin. Compound 65 exhibited the prominent 
inhibition of AChE and it also showed selectivity for AChE 
(IC50 = 0.187 ± 0.015 μM) than BuChE (IC50 = 12.4 ± 1.03 
μM). Compound 65 also showed inhibition (45.3 ± 3.58%) 
of Aβ aggregation. This compound also penetrated BBB 
(Pe = 11.85 ± 1.00) and showed antioxidant activity 
(3.07 ± 0.04 μmol) (Yan et al., 2017). Shen et al. (2009) 
linked N-benzylpiperidine part of donepezil to various 
flavonoids to produce the new hybrid molecules. Among 
these derivatives, Compound 66 exhibited the most 
effective inhibition of AChE with an IC50 value of 0.093 
μM. Compound 66 showed increased selectivity for AChE 
as compared to BuChE. Compounds having oxygen 
linker were found to be more active as compared to the 
methoxy group. Molecular docking investigations of 
this compound with AChE showed that isoflavone part 
FIGURE 9 - Donepezil hybrids molecules with natural compounds.
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of compound 66 joined the peripheral pocket through 
hydrophobic interactions. Two hydrogen bonds were also 
observed for this compound with Ser286 and Arg289. 
Compound 66 showed a binding free energy of -22.28 
kcal/mol (Shen et al., 2009). Rodriguez-Franco et al. 
(2005) also linked benzylpiperidine and benzylpyridine 
to 8-substituted xanthine derived from theophylline. 
Methoxymethyl group was used as a linker group between 
these two pharmacophores. These compounds exhibited 
AChE and BuChE inhibitory activities. Compound 67 
showed prominent activity in this series presenting an 
IC50 value of 0.1 ± 0.01 μM for AChE. Compound 68 was 
the most active inhibitor of the BuChE with an IC50 value 
of 0.4 ± 0.01 μM. Therefore it was noted that compounds 
having benzylpyridine part showed better interaction with 
AChE. The additional aromatic ring interacted with the 
aromatic amino acid of AChE (Rodríguez-Franco et al., 
2005). 
Donepezil derivatives having propargylamine 
group 
The presence of  propargylamine group in 
certain drugs such as rasagiline and ladostigil confer 
neuroprotective, antiapoptotic and Aβ aggregation 
inhibitory properties (Bar-Am et al., 2010). Bautista-
Aguilera et al. carried out the synthesis of new donepezil 
and indole hybrid molecules as anti-Alzheimer agents. 
In this compound, benzylpiperidine was attached to the 
position # 5 of indole through three methylene units and 
propargylamine group was attached at position # 2 of 
the indole ring. Compound 69 (Figure 10) was found to 
be the most potent agent in this class. It showed potent 
human MAO-A (IC50 = 0.0055 ± 0.0014 μM) inhibitory 
activity as well as selectivity as compared to human 
MAO-B (IC50 = 0.15 ± 0.031nM). Compound 69 also 
exhibited AChE (IC50= 0.19 ± 0.01 μM) and BuChE 
(IC50 = 0.83 ± 0.16 μM) inhibitory activities. Docking 
studies with AChE showed that propargylamine interacted 
via π-π bonding with Trp86. Phenyl ring interacted 
with the PAS and compound showed the binding free 
energy of -11.9 kcal/mol (Bautista-Aguilera et al., 2014). 
Bolea et al. synthesized some multitarget molecules in 
which benzylpiperidine part of donepezil and indole 
propargylamine part of MAO inhibitor N-[(5-benzyloxy-
1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-
yn-1-amine were conjugated. Resultant compounds 
showed the capacity to interact with cholinesterases 
and MAO enzymes. Compound 70 exhibited prominent 
activity having MAO-A (IC50 = 5.2 ± 1.1 nM), MAO-B 
(IC50 = 43 ± 8 nM), AChE (IC50 = 0.35 ± 0.01 nM), 
BuChE (IC50 = 0.46 ± 0.06 nM) inhibitory activities. 
Compound 70 also showed the inhibition (32.4 ± 7.0%) 
of Aβ aggregation. Molecular docking studies revealed 
that benzylpiperidine fragment attached with catalytic 
site and indole propargylamine part is stacked between 
aromatic rings with Trp279 and Tyr334. Propargylamine 
formed van der Waals interaction with phenyl ring 
of Tyr70 (Bolea et al., 2011). Wang et al. (2014) 
synthesized hybrid compounds in which structural parts of 
donepezil, propargylamine and 8-hydroxyquinoline were 
combined. Compound 71 was the most active compound 
and showed simultaneous inhibition of MAO-A and 
MAO-B presenting IC50 values of 6.2 μM and 10.2 μM 
respectively. Significant AChE (IC50 = 1.8 ± 0.1 μM) and 
BuChE (IC50 = 1.6 ± 0.25 μM) inhibitory values were also 
observed for this compound. Compound 71 also showed 
excellent pharmacokinetic properties and displayed 
less toxicity to HepG2 cell line. Compound 71 contains 
8-hydroxyquinoline and N-benzylpiperidine attached to 
the central propargylamine part having a nitrile group. 
This compound is a racemic mixture and both isomers 
showed binding at PAS and CAS of electric eel AChE 
(Wang et al., 2014). Later on, Wu et al. (2016) also 
FIGURE 10 - Propargylamine derivatives of donepezil.
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combined propargylamine group with benzylpiperidine 
and quinoline to produce new hybrid molecules. Among 
these derivatives, compound 72 showed excellent 
inhibition of AChE (IC50 = 0.029 ± 0.003 μM), BuChE 
(IC50 = 0.039 ± 0.003 μM) and selective MAO-A inhibition 
(IC50 =10.1 ± 1.1 μM). Compound 72 also showed metal 
chelating and antioxidant properties. The potency of 
compound 72 for cholinesterases was linked to the 
appropriate distance between the aromatic part and basic 
centre which are necessary for interaction with PAS, 
mid-gorge and CAS of AChE. Compound 72 is the bigger 
derivative in this series and cyano group can interact with 
mid gorge because of the correct length (Wu et al., 2016). 
Attachment of benzyl piperidine and benzyl 
piperazine with condensed heterocyclic rings
Vila et al. (2016) carried out the synthesis of 
donepezil analogues in which the indanone part 
of donepezil was replaced by the phthalazinone 
nucleus and the phthalazinone was connected to the 
N-benzylpiperidine fragment through the alkyl chain of 
two to three carbons. Compound 73 was prominently 
active and found to be the equipotent inhibitor of AChE 
and BuChE having IC50 values of 3.45 ± 0.23 μM and 
5.50 ± 0.37 μM. Compound 73 (Figure 11) contains 
p-toluyl group at position # 4 of the phthalazinone 
ring which gives an additional hydrophobic interaction 
with cholinesterases. Docking studies also showed 
dual binding of this compound with AChE as well as 
with BuChE (Vila et al., 2016). Pudlo et al. connected 
quinoline carboxamide to the benzylpiperidine to 
produce the new hybrid molecules. These compounds 
exhibited the better inhibition of AChE as compared to 
BuChE. Compounds 74 and 75 were most active having 
IC50 values of 0.11 ± 0.03 μM and 0.48 ± 0.14 μM. 
Compound 75 also showed highest antioxidant activity 
(EC50 = 12.2 ± 0.4 μM) and it contains catechol ring. 
Catechol ring was found to be important for antioxidant 
activity. Docking studies of compound 75 showed 
that phenyl group formed π-π interactions with CAS, 
piperidinium interacted with gorge and quinoline part 
was attached with PAS of AChE (Pudlo et al., 2014). 
Synthesis of donepezil-Trolox hybrid molecules 
was reported by Cai et al. (2017). These compounds 
demonstrated activity against AChE and MAO-B 
enzymes. The most potent compound 76 showed 
inhibition of human AChE and MAO-B with IC50 values 
of 0.54 μM and 4.3 μM respectively. This compound also 
showed significant antioxidant activity (IC50 = 41.33 μM) 
and less hepatotoxicity to cell lines PC12, HePG2 and 
BV-2 (Cai et al., 2017). N-benzylpiperidine fragment 
of donepezil and melatonin were fused together to 
produce the new molecules. Most of the compounds 
showed higher inhibition of BuChE as compared to 
AChE. Compound 77 was the excellent inhibitor of 
electric AChE and equine BuChE having IC50 values of 
193 nM and 73 nM. This compound also displayed Aβ 
aggregation (56.3%) inhibition and antioxidant activities 
(3.28 Trolox equivalent). It also showed the capacity to 
penetrate into CNS. Molecular modeling studies showed 
that compound 77 interacted with CAS and PAS of AChE 
(Wang et al., 2016). 
Ismail et al. (2012b) carried out the synthesis 
of donepezil derivatives in which the indanone part 
of donepezil was substituted by tetrahydrobenzo[b]
thiophine ring having carbonyl group at position # 3 
of tetrahydrobenzo[b]thiophine. Acetamide group was 
introduced as a linker between the tetrahydrobenzo[b]
thiophine and benzylpiperidine. Compounds 78 and 79 
FIGURE 11 - Donepezil derivatives having condensed heterocyclic rings.
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(Figure 12) exhibited prominent inhibition (56.67%, 
60% for 78 and 79) of AChE which was better than the 
standard drug donepezil (40%). In molecular docking 
studies, compound 78 presented strong hydrogen bonding 
than donepezil, which may be due to the amide group 
(Ismail et al., 2012b). Omran et al. (2005) carried out the 
synthesis of new indanones and thiaindanones derivatives 
and evaluated their AChE inhibitory activity. Compound 80 
exhibited excellent inhibition of AChE having an IC50 value 
of 0.06 μM as compared to donepezil (IC50 = 0.02 μM). 
It contains oxime group in the thiaindanone part and 
thiaindanone is attached to 2-fluorobenzyl piperazine 
through acetamide linker. Molecular modeling studies 
were also carried out and it was observed that fluorine 
atom at the ortho position of the benzyl group amplified 
the π-π interaction with the AChE enzyme (Omran et al., 
2005). Omran et al. (2008) carried out further modification 
and compound 81 was the most active inhibitor of AChE 
showing an IC50 value of 0.5 μM. It was observed that the 
replacement of the piperazine ring leads to the formation 
of inactive compounds. Replacement of hydroxyl group of 
this molecule with the bromine or fluorine produced less 
active compounds (Omran et al., 2008).
DISCUSSION
A literature review of donepezil showed that 
benzylpiperidine part of donepezil can be replaced 
with benzylpyridine, benzylpiperazine, pyridyl 
methylpiperidine, aniline and phenylpiperazine motifs 
FIGURE 12 - Donepezil derivatives having condensed heterocyclic rings.
with the retention of activity as anti-Alzheimer agents. 
Replacement of benzylpiperidine with unsubstituted 
piperidine produced less active compounds. 3-Hydroxy-6-
(piperidin-1-ylmethyl)picolinaldehyde oxime derivatives 
were found to be reactivator of the AChE. Alkylamine, 
carboxamide and acylhydrazone are most commonly used 
linkers in these molecules. Attachment of benzylpiperidine 
with heterocyclic rings such as pyridine showed AChE 
and BuChE inhibitory activity while the picolinamide 
derivative showed MAO inhibition in addition to 
cholinesterase inhibitory activity. Benzylpiperidine part 
of donepezil has also been attached with condensed 
heterocyclic rings such as phthalazine, quinoline, 
tetrahydrobenzothiophine, indole and Trolox and 
these molecules showed anti-Alzheimer activities. 
Propargylamine derived compounds also exhibited 
MAO inhibition in addition to cholinesterase inhibition 
properties. In some derivatives, indanone part has been 
replaced with tetralone, oxindole, and phthalimide with 
retention of activity. Hybrid molecules of donepezil with 
ferulic acid showed higher BuChE inhibitory activity as 
compared to AChE inhibitory activity. These compounds 
also showed antioxidant as well as Aβ aggregation 
inhibitory activities. Hybrid molecules of donepezil with 
tacrine produced compounds having AChE and BuChE 
inhibition. Donepezil hybrid molecules with natural 
compounds like flavonoids, coumarins, and curcumin 
presented antioxidant and MAO inhibitory activities in 
addition to cholinesterase inhibition. Amino acid derived 
compounds of donepezil showed dual inhibition of AChE 
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and BuChE enzymes. In this review, we have summarized 
the recent research progress of donepezil derived anti-
Alzheimer agents. This review can help to provide some 
useful information for organic and medicinal chemists 
working in this field.
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